Effect of Tea Consumption on Steroid Profile in Healthy Volunteers
NCT ID: NCT02779361
Last Updated: 2017-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
29 participants
INTERVENTIONAL
2016-01-31
2017-02-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does a Multi-ingredient Pre-workout Supplement Enhance Cycling Time Trial Performance?
NCT05230862
How Does Altering the Timing of Pre-exercise Low-dose Caffeine Ingestion Affect Endurance Exercise Performance
NCT02985606
Effects of Different Sports Supplements on Metabolism and Perceptual Responses During Distance Running
NCT03596788
Placebo Controlled Study for Characterisation of Immunological Effects and Safety of Active O2
NCT01333930
Green Tea Supplementation, Fat Oxidation and Body Composition in Overweight Individuals
NCT04628624
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Testosterone glucuronization by UGT2B17 isoenzyme (Uridine Diphosphate Glucuronyltransferase 2B17) is inhibited in vitro by green tea flavonols like epicatechin, epigallocatechin gallate (EGCG) and catechin gallate.
Therefore a diet rich in green tea could interfere in androgens' glucuronization and cause a change on the steroid profile of the athletes that could be considered a false positive.
A clinical trial designed to assess changes on steroid profile in healthy volunteers after green tea consumption will be conducted. Subjects with different UGT2B17 genotype will be recruited (10 of each type: ins/ins, ins/del, del/del) to study if the genotype can modulate the results obtained.
Urine samples obtained before and during 7 days of green tea consumption will be used to compare steroid profile. Blood samples will be also collected to assess EGCG pharmacokinetics.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Green tea
Green tea consumption along 7 days.
Green tea
Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (\*), 10:30 am, 13:00 pm (\*), 15:30 pm, 18:00 pm (\*), 20:30 pm on day 7.
One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (\*).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Green tea
Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (\*), 10:30 am, 13:00 pm (\*), 15:30 pm, 18:00 pm (\*), 20:30 pm on day 7.
One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (\*).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI=weight/heigth2) between 19 and 27 kg/m2, weight between 50 and 100 kg.
* No evidence of somatic or psychiatric disorders as per past medical history and physical examination
* EKG, blood and urine tests taken before entry into the study within the normal range. Minor and transient abnormalities may be acceptable if, according to the Principal Investigator's criterion and the state of the art, they are felt to have no clinical relevance, entail no danger to the participant, and don't interfere with the product's assessment. These abnormalities and their non-relevance must be specifically justified in writing)
Exclusion Criteria
* Previous psychiatric disorders, alcoholism, abuse of prescription drugs or illegal substances or regular consumption of psychoactive drugs
* Having donated blood or having participated in this same study in the preceding 8 weeks, or having participated in any clinical trial with drugs in the preceding 12 weeks
* Having had any somatic disease or having undergone major surgery in the 3 months prior to inclusion in the trial
* Individuals intolerant or having experienced a severe adverse reaction to green tea or caffeine
* Having regularly taken medication in the month before the trial, except for vitamins, herb-based remedies, dietary supplements that if, according to the Principal Investigator or his appointed collaborators' opinion, they pose no threat to the subjects and they won't interfere with the study's objectives. Single doses of symptomatic drugs taken during the week before the experimental session will not constitute an exclusion criterion if it can be assumed that it has been completely eliminated on the day of the experimental session
* Smokers of \>10 cigarettes/day
* Consumption of \>40 g/day of alcohol
* Daily consumption of less than one xanthine-containing beverages per day
* Hepatitis B, hepatitis C or human immunodeficiency virus-positive individuals
* Vegetarian subjects or with aberrant diets
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
World Anti-Doping Agency
OTHER
Parc de Salut Mar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Clara Pérez
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rosa Ventura, PhD
Role: STUDY_DIRECTOR
World Anti-Doping Agency
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parc de Salut Mar-IMIM
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMIMFTCL/EGCG/3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.